Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

August 26, 2013

Primary Completion Date

August 6, 2016

Study Completion Date

November 10, 2016

Conditions
Coronary Artery Disease
Interventions
DRUG

Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.

Trial Locations (24)

4032

Chermside

5006

North Adelaide

5042

Adelaide

6000

Perth

19104

Philadelphia

20814

Bethesda

20892

Bethesda

22908

Charlottesville

27710

Durham

29425

Charleston

30322

Atlanta

43210

Columbus

44195

Cleveland

63110

St Louis

77030

Houston

85724

Tucson

168752

Singapore

90048-0750

Los Angeles

60611-2908

Chicago

02114

Boston

N6A 5A5

London

H1T 1C8

Montreal

H4A 3J1

Montreal

Unknown

Singapore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01890434 - Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) | Biotech Hunter | Biotech Hunter